<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923299</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000636018</org_study_id>
    <secondary_id>CLCC-THERAPY</secondary_id>
    <secondary_id>RECF0910</secondary_id>
    <secondary_id>VA-2008/34</secondary_id>
    <secondary_id>EUDRACT-2008-003988-39</secondary_id>
    <nct_id>NCT00923299</nct_id>
  </id_info>
  <brief_title>Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine</brief_title>
  <acronym>THERAPY</acronym>
  <official_title>Phase I-II Study Evaluating Combined Treatment of Cetuximab and Trastuzumab in Metastatic Pancreatic Cancer Patients Progressing After Gemcitabine Based Chemotherapy.(THERAPY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as cetuximab and trastuzumab, can block tumor growth&#xD;
      in different ways. Some block the ability of tumor cells to grow and spread. Others find&#xD;
      tumor cells and help kill them or carry tumor-killing substances to them. Giving cetuximab&#xD;
      together with trastuzumab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of trastuzumab when&#xD;
      given together with cetuximab and to see how well it works in treating patients with&#xD;
      metastatic pancreatic cancer that progressed after previous treatment with gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the recommended dose of trastuzumab when given with cetuximab in patients with&#xD;
           metastatic pancreatic cancer that progressed after gemcitabine-based chemotherapy.&#xD;
           (Phase I)&#xD;
&#xD;
        -  Evaluate the objective response rate as assessed by RECIST criteria. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the safety profile as assessed by NCI CTCAE v3.0.&#xD;
&#xD;
        -  Evaluate progression-free survival.&#xD;
&#xD;
        -  Evaluate overall survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study of trastuzumab followed by a&#xD;
      phase II study.&#xD;
&#xD;
      Patients receive cetuximab IV over 1-2 hours and trastuzumab IV over 30-90 minutes on day 1.&#xD;
      Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose of trastuzumab when given with cetuximab (Phase I)</measure>
    <time_frame>15 days</time_frame>
    <description>From baseline to the end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate as assessed by RECIST criteria (Phase II)</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>From baseline to the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>From baseline to the end of study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>cetuximab, trastuzumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.</description>
    <arm_group_label>cetuximab, trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Two dose levels of trastuzumab will be evaluated for Phase 1:&#xD;
Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;&#xD;
Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations.</description>
    <arm_group_label>cetuximab, trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Progressed after first-line or adjuvant gemcitabine-based chemotherapy&#xD;
&#xD;
          -  Measurable disease as assessed by RECIST criteria&#xD;
&#xD;
          -  No known brain metastasis or symptomatic carcinomatous leptomeningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 2.5 times ULN&#xD;
&#xD;
          -  ALT/AST ≤ 5 times ULN&#xD;
&#xD;
          -  LVEF ≥ 55%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No significant comorbidities, including any of the following:&#xD;
&#xD;
               -  Cardiovascular disease&#xD;
&#xD;
               -  Documented history of congestive heart failure&#xD;
&#xD;
               -  Uncontrolled, high-risk arrhythmia&#xD;
&#xD;
               -  Angina pectoris requiring treatment&#xD;
&#xD;
               -  Clinically significant valvular disease&#xD;
&#xD;
               -  Evidence of transmural myocardial infarction by ECG&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Active bleeding&#xD;
&#xD;
               -  Clinically significant active infection&#xD;
&#xD;
               -  Severe dyspnea at rest&#xD;
&#xD;
               -  Oxygen-dependency&#xD;
&#xD;
          -  No other malignancy except basal cell carcinoma of the skin&#xD;
&#xD;
          -  No severe hypersensitivity to cetuximab or trastuzumab&#xD;
&#xD;
          -  No medical or psychological condition that would preclude study completion or giving&#xD;
             informed consent&#xD;
&#xD;
          -  No legal incapacity or limited legal capacity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior cetuximab or trastuzumab&#xD;
&#xD;
          -  No other concurrent experimental drugs or anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Ychou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the &quot;THERAPY&quot;phase 1-2 trial. Oncotarget. 2015 May 20;6(14):12796-808.</citation>
    <PMID>25918250</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

